Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
IPO Year: 2014
Exchange: NASDAQ
Website: adamaspharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2021 | $8.50 | Outperform → Market Perform | Northland Capital Markets |
| 10/12/2021 | Market Outperform → Market Perform | JMP Securities | |
| 10/12/2021 | $7.00 → $8.00 | Overweight → Neutral | Piper Sandler |
| 10/12/2021 | $10.00 → $9.10 | Buy → Neutral | HC Wainwright & Co. |
| 10/11/2021 | Outperform → Market Perform | William Blair |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)
4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)
4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)
4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)
4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)
4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)
4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)
4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)
4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)
4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Northland Capital Markets downgraded Adamas Pharmaceuticals from Outperform to Market Perform and set a new price target of $8.50
JMP Securities downgraded Adamas Pharmaceuticals from Market Outperform to Market Perform
Piper Sandler downgraded Adamas Pharmaceuticals from Overweight to Neutral and set a new price target of $8.00 from $7.00 previously
HC Wainwright & Co. downgraded Adamas Pharmaceuticals from Buy to Neutral and set a new price target of $9.10 from $10.00 previously
William Blair downgraded Adamas Pharmaceuticals from Outperform to Market Perform
HC Wainwright & Co. reiterated coverage of Adamas Pharmaceuticals with a rating of Buy and set a new price target of $10.00 from $12.00 previously
H.C. Wainwright reiterated coverage of Adamas Pharmaceuticals with a rating of Buy and set a new price target of $12.00 from $10.00 previously
15-12B - Adamas Pharmaceuticals Inc (0001328143) (Filer)
EFFECT - Adamas Pharmaceuticals Inc (0001328143) (Filer)
S-8 POS - Adamas Pharmaceuticals Inc (0001328143) (Filer)
S-8 POS - Adamas Pharmaceuticals Inc (0001328143) (Filer)
S-8 POS - Adamas Pharmaceuticals Inc (0001328143) (Filer)
S-8 POS - Adamas Pharmaceuticals Inc (0001328143) (Filer)
S-8 POS - Adamas Pharmaceuticals Inc (0001328143) (Filer)
S-8 POS - Adamas Pharmaceuticals Inc (0001328143) (Filer)
S-8 POS - Adamas Pharmaceuticals Inc (0001328143) (Filer)
S-8 POS - Adamas Pharmaceuticals Inc (0001328143) (Filer)
Fastest customizable press release news feed in the world
ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). "Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "In addition, the acquisition adds a new growth catalyst, diversifies our revenue base and cash flow, and is expected to be significantly accretive in 2022." Compelling Strategic Rationale Strengthens Parkinson's disease portfolio with GOCOVRI® (amantadine) extended r
ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus' proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) expired at 11:59 p.m. on November 22, 2021. On October 21, 2021, Supernus and Adamas filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice. The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the Offer (as defined below). The Off
Acquisition of two marketed products diversifies and accelerates revenue and cash flowExpected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructureTotal consideration up to $9.10 per share. Upfront cash payment of $8.10 per share with fully diluted equity value of approximately $400 million, plus $1.00 contingent value right based on net sales of GOCOVRI®Conference call and webcast today at 8:30 a.m. ET to discuss the transaction ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS),
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted eight new employees restricted stock units to acquire 106,500 shares of the company's common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company. About Adamas Pharmaceuticals, Inc. At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been selected as one of five finalists in the UCSF Health Awards 2021 New Therapeutics category. This year's UCSF Health Awards program, which historically focused on the digital health tech industry, was expanded to include several life science categories. Companies selected as finalists have been evaluated on innovation, impact, and value of their product to improve patient outcomes. Adamas' new therapeutic is GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approv
PALO ALTO, Calif., Sept. 30, 2021 /PRNewswire/ -- Cognoa, a pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with behavioral health conditions, today announced that Tony Rimac has joined as Chief Financial Officer (CFO). Rimac joins Cognoa's management team to lead the development and implementation of the company's financial strategy. "We are thrilled to welcome Tony to the Cognoa team and look forward to leveraging his financial and strategic leadership abilities. Tony has a wealth of private and public industry experien
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced five posters will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, taking place September 17 – 22, 2021. The poster presentations will focus on GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidop
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted seven new employees restricted stock units to acquire 94,750 shares of the company's common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company. About Adamas Pharmaceuticals, Inc. At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of n
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that management will present at the following virtual investor conferences during the month of September 2021: H.C. Wainwright 23rd Annual Global Investment Conference, a pre-recorded presentation will be available beginning on Monday, September 13 at 7:00 am ET (4:00 am PT) Cantor Fitzgerald Global Healthcare Conference, on Wednesday, September 29 at 4:40 pm ET (1:40 pm PT) Replays of both events will be available on the investor relations section of the Adamas website at http://ir.adamas
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted three new employees restricted stock units to acquire 38,500 shares of the company's common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company. About Adamas Pharmaceuticals, Inc. At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of n
Live finance-specific insights
ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). "Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "In addition, the acquisition adds a new growth catalyst, diversifies our revenue base and cash flow, and is expected to be significantly accretive in 2022." Compelling Strategic Rationale Strengthens Parkinson's disease portfolio with GOCOVRI® (amantadine) extended r
Acquisition of two marketed products diversifies and accelerates revenue and cash flowExpected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructureTotal consideration up to $9.10 per share. Upfront cash payment of $8.10 per share with fully diluted equity value of approximately $400 million, plus $1.00 contingent value right based on net sales of GOCOVRI®Conference call and webcast today at 8:30 a.m. ET to discuss the transaction ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS),
Second quarter 2021 total revenues of $22.0 million, a 17% increase over second quarter 2020 GOCOVRI new paid prescriptions of 730, a 97% increase over second quarter 2020 Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the second quarter ended June 30, 2021, and recent corporate highlights. "We delivered a strong performance in the second quarter, with a robust increase in demand set to fuel future growth," said Neil F. McFarlane, Chief Executive Officer. "We remain on track to achieve our 2021 goals as we navigate the
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the company will report second quarter 2021 financial results on Monday, August 9, after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. Investor Conference Call and Webcast The conference call can be accessed by dialing 1-877-407-9716 for participants in the U.S. or Canada and 1-201-493-6779 for international callers. All callers must provide the following Conference ID: 13720109. The webcast can be accessed live via the investor section of the Adamas website at https://ir.adamaspharma.com/e
EMERYVILLE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has entered into an agreement to amend certain key terms of its Royalty-Backed Loan agreement (“Royalty-Backed Loan”) with HealthCare Royalty Partners (“HCR”). The key terms amended are summarized as follows: Revised to provide for repayment from a royalty on OSMOLEX ER® on the same terms as, and in addition to, the royalty for GOCOVRI®. Eliminated the potential royalty rate step-up to 17.5%, which would have occurred in 2022 if
EMERYVILLE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has signed an agreement to settle its ongoing patent litigation with Osmotica Pharmaceutical US LLC, a subsidiary of Osmotica Pharmaceuticals plc. As a result of this agreement, both parties will drop their respective claims relating to the patent litigation, and Adamas will acquire the global rights to OSMOLEX ER® for $7.5 million. The agreement is expected to close early in 2021. Adamas’ current portfolio consists of GOCOVRI® (amantad
This live feed shows all institutional transactions in real time.
SC 13G/A - Adamas Pharmaceuticals Inc (0001328143) (Subject)
SC 13G/A - Adamas Pharmaceuticals Inc (0001328143) (Subject)
SC 13D - Adamas Pharmaceuticals Inc (0001328143) (Subject)
SC 13G - Adamas Pharmaceuticals Inc (0001328143) (Subject)
SC 13G - Adamas Pharmaceuticals Inc (0001328143) (Subject)
SC 13G/A - Adamas Pharmaceuticals Inc (0001328143) (Subject)
SC 13G/A - Adamas Pharmaceuticals Inc (0001328143) (Subject)
SC 13G/A - Adamas Pharmaceuticals Inc (0001328143) (Subject)
SC 13G/A - Adamas Pharmaceuticals Inc (0001328143) (Subject)